Chugai Pharmaceutical Co Ltd - Company Profile
Powered by 
All the data and insights you need on Chugai Pharmaceutical Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Chugai Pharmaceutical Co Ltd Strategy Report
- Understand Chugai Pharmaceutical Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Chugai Pharmaceutical Co Ltd (Chugai), a subsidiary of F. Hoffmann-La Roche Ltd, is focused on the research, development, commercialization, manufacturing, import and export of biopharmaceuticals and therapeutic antibodies. The company offers products for the treatment of various therapeutic areas including, cancer; bone and joint diseases; renal diseases; immune disorders and infectious diseases and others. It also offers drugs to aid the kidney, liver and other organ transplants. The company is operating through its network of subsidiaries, the company offers its pharmaceutical products in overseas markets including North America, Europe and Asia. Chugai is headquartered in Tokyo, Japan.
Headquarters
Japan
Address
15f, Nihonbashi Mitsui Tower, 2-1-1, Nihonbashi-Muro-Machi, Chuo-Ku, Tokyo, 103-8324
Website
www.chugai-pharm.co.jp
Telephone
81 3 32816611
No of Employees
7,771
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4519 (TYO)
Revenue (2022)
$8.2B
-11.8%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-13.1%
(2022 vs 2021)
Market Cap*
$57.4B
Net Profit Margin (2022)
XYZ
-1.5%
(2022 vs 2021)
* As of and is in US$
Chugai Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Marketed | Actemra |
| Oncology: | Avastin |
| Actemra | Alecensa |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In March, the company received approval from the Ministry of Health, Labour and Welfare for the anti-VEGF/anti-Ang-2 bispecific antibody Vabysmo Intravitreal Injection 120 mg/mL for an additional indication of the treatment of macular edema associated with retinal vein occlusion. |
| 2024 | Regulatory Approval | In February, the company received approval from the Ministry of Health, Labour and Welfare for FoundationOne CDx Cancer Genomic Profile as a companion diagnostic for Pfizer Japan's talazoparib. |
| 2023 | New Products/Services | In November, the company launched Phesgo, a subcutaneous combination of pertuzumab and trastuzumab for the treatment of HER2-positive breast and colorectal cancer. |
Competitor Comparison
| Key Parameters | Chugai Pharmaceutical Co Ltd | Daiichi Sankyo Co Ltd | Sumitomo Pharma Co Ltd | Mitsubishi Tanabe Pharma Corp | Kyowa Kirin Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Chuo-Ku | Chuo-Ku | Osaka-Shi | Osaka | Chiyoda-Ku |
| State/Province | Tokyo | Tokyo | Osaka | Osaka | Tokyo |
| No. of Employees | 7,771 | 17,435 | 6,250 | 6,697 | 5,974 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Osamu Okuda | President; Director - Representative; Chief Executive Officer | Executive Board | 2021 | 59 |
| Toshiaki Itagaki | Director; Executive Vice President; Chief Financial Officer | Executive Board | 2022 | 62 |
| Hisafumi Yamada | Director; Executive Vice President | Executive Board | 2022 | 66 |
| Tetsuya Yamaguchi | Executive Vice President; Head - Project & Lifecycle Management Unit | Senior Management | 2023 | - |
| Kaori Ouchi | Vice President; Head - Medical Affairs Division | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward